中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Heme Catabolic Pathway in Inflammation and Immune Disorders

文献类型：期刊论文

作者Wu, Bing1,2; Wu, Yanwei1,2; Tang, Wei1,2
刊名FRONTIERS IN PHARMACOLOGY
出版日期2019-07-24
卷号10页码:15
关键词heme heme oxygenase carbon monoxide biliverdin inflammation immune disorders
ISSN号1663-9812
DOI10.3389/fphar.2019.00825
通讯作者Wu, Yanwei(wuyanwei@simm.ac.cn) ; Tang, Wei(tangwei@simm.ac.cn)
英文摘要In recent years, the heme catabolic pathway is considered to play an important regulatory role in cell protection, apoptosis, inflammation, and other physiological and pathological processes. An appropriate amount of heme forms the basic elements of various life activities, while when released in large quantities, it can induce toxicity by mediating oxidative stress and inflammation. Heme oxygenase (HO) - 1 can catabolize free heme into carbon monoxide (CO), ferrous iron, and biliverdin (BV)/bilirubin (BR). The diverse functions of these metabolites in immune systems are fascinating. Decades work shows that administration of degradation products of heme such as CO and BV/BR exerts protective activities in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS) and other immune disorders. This review elaborates the molecular and biochemical characterization of heme catabolic pathway, discusses the signal transduction and immunomodulatory mechanism in inflammation and summarizes the promising therapeutic strategies based on this pathway in inflammatory and immune disorders.
WOS关键词C-REACTIVE PROTEIN ; CORNEAL EPITHELIAL-CELLS ; NF-KAPPA-B ; SYSTEMIC-LUPUS-ERYTHEMATOSUS ; HUMAN BILIVERDIN REDUCTASE ; CARBON-MONOXIDE SUPPRESS ; SYNOVIAL-FLUID FERRITIN ; SERUM FERRITIN ; NUCLEAR FERRITIN ; UNCONJUGATED BILIRUBIN
资助项目National Science Fair Committee (NSFC), China[81673445] ; National Science Fair Committee (NSFC), China[81803543] ; Personalized Medicines-Molecular Signature-based Drug Discovery and Development, Strategic Priority Research Program of the Chinese Academy of Sciences[DA12020107] ; National Science & Technology Major Project New Drug Creation and Manufacturing Program,'' China[2017ZX09101002-002010] ; Shanghai Committee of Science and Technology, China[16431900300]
WOS研究方向Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000476865300001
出版者FRONTIERS MEDIA SA
源URL[http://119.78.100.183/handle/2S10ELR8/289081]  
专题中国科学院上海药物研究所
通讯作者Wu, Yanwei; Tang, Wei
作者单位1.Chinese Acad Sci, Shanghai Inst Materia Med, Lab Immunopharmacol, Shanghai, Peoples R China
2.Univ Chinese Acad Sci, Sch Pharm, Beijing, Peoples R China
推荐引用方式
GB/T 7714		 Wu, Bing,Wu, Yanwei,Tang, Wei. Heme Catabolic Pathway in Inflammation and Immune Disorders[J]. FRONTIERS IN PHARMACOLOGY,2019,10:15.
APA Wu, Bing,Wu, Yanwei,&Tang, Wei.(2019).Heme Catabolic Pathway in Inflammation and Immune Disorders.FRONTIERS IN PHARMACOLOGY,10,15.
MLA Wu, Bing,et al."Heme Catabolic Pathway in Inflammation and Immune Disorders".FRONTIERS IN PHARMACOLOGY 10(2019):15.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。